Biocartis Idylla Liquid Biopsy and Colorectal Cancer Assays
Biocartis has launched two new research-use-only products for its Idylla molecular diagnostics platform. The first product, the Idylla ctBRAF Mutation Assay, uses blood plasma as a sample, and according to the company is the first fully automated liquid biopsy assay that can potentially act as a substitute for tissue biopsy testing in melanoma, colorectal, and lung cancers, as well as conditions such as hairy cell leukemia and histiocytosis. The assay has a turnaround time of approximately 90 minutes with less than one minute of hands-on time.
The second product, the Idylla NRAS-BRAF-EGFR S492R Mutation Assay complements the already CE-marked Idylla KRAS Mutation Test. Together, these provide complete metastatic colorectal cancer mutation analysis using two slices of formalin-fixed, paraffin-embedded tumor tissue.